» Articles » PMID: 28599212

Dose-related Effects of Delta-9-THC on Emotional Responses to Acute Psychosocial Stress

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2017 Jun 10
PMID 28599212
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Cannabis smokers often report that they use the drug to relax or to relieve emotional stress. However, few clinical studies have shown evidence of the stress-relieving effects of cannabis or cannabinoid agonists. In this study, we sought to assess the influence of delta-9-tetrahydrocannabinol (THC), a main active ingredient of cannabis, upon emotional responses to an acute psychosocial stressor among healthy young adults.

Methods: Healthy volunteers (N=42) participated in two experimental sessions, one with psychosocial stress (Trier Social Stress Test, TSST) and another with a non-stressful task, after receiving 0 (N=13), 7.5mg (N=14) or 12.5mg (N=15) oral THC. Capsules were administered under randomized, double blind conditions, 2.5h before the tasks began. We measured subjective mood and drug effects, vital signs and salivary cortisol before and at repeated times after the capsule and tasks. Subjects also appraised the tasks, before and after completion.

Results: In comparison to placebo, 7.5mg THC significantly reduced self-reported subjective distress after the TSST and attenuated post-task appraisals of the TSST as threatening and challenging. By contrast, 12.5mg THC increased negative mood overall i.e., both before and throughout the tasks, and pre-task ratings of the TSST as threatening and challenging. It also impaired TSST performance and attenuated blood pressure reactivity to the stressor.

Conclusions: Our findings suggest that a low dose of THC produces subjective stress-relieving effects in line with those commonly reported among cannabis users, but that higher doses may non-specifically increase negative mood.

Citing Articles

Understanding Suicidal Thoughts and Behaviors Among LGBTQ + Youth: Differential Associations Between Bullying and Substance Use.

Tiedge C, Valido A, Rivas-Koehl M, Garcia B, Robinson L, Clements G Prev Sci. 2025; .

PMID: 39934543 DOI: 10.1007/s11121-025-01783-1.


Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.

Kumar U Int J Mol Sci. 2025; 26(1.

PMID: 39796008 PMC: 11720483. DOI: 10.3390/ijms26010152.


Cannabis use, oral dysbiosis, and neurological disorders.

Hazzard A, McCrorey M, Salman T, Johnson D, Luo Z, Fu X NeuroImmune Pharm Ther. 2025; 3(3-4):183-193.

PMID: 39741560 PMC: 11683879. DOI: 10.1515/nipt-2024-0012.


Multimodal examination of daily stress rhythms in chronic Cannabis users.

Glodosky N, Cleveland M, Azghan R, Ghasemzadeh H, McLaughlin R, Cuttler C Psychopharmacology (Berl). 2024; .

PMID: 39500774 DOI: 10.1007/s00213-024-06709-3.


Effects of cannabidiol, with and without ∆9-tetrahydrocannabinol, on anxiety-like behavior following alcohol withdrawal in mice.

Melkumyan M, Annaswamy V, Evans A, Showemimo O, McCullers Z, Sun D Front Neurosci. 2024; 18:1375440.

PMID: 38957186 PMC: 11217543. DOI: 10.3389/fnins.2024.1375440.


References
1.
Kirk J, de Wit H . Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav. 1999; 63(1):137-42. DOI: 10.1016/s0091-3057(98)00264-0. View

2.
Simons J, Correia C, Carey K . A comparison of motives for marijuana and alcohol use among experienced users. Addict Behav. 2000; 25(1):153-60. DOI: 10.1016/s0306-4603(98)00104-x. View

3.
LeDoux J . Emotion circuits in the brain. Annu Rev Neurosci. 2000; 23:155-84. DOI: 10.1146/annurev.neuro.23.1.155. View

4.
Davis M, Whalen P . The amygdala: vigilance and emotion. Mol Psychiatry. 2001; 6(1):13-34. DOI: 10.1038/sj.mp.4000812. View

5.
Hart C, Van Gorp W, Haney M, Foltin R, FISCHMAN M . Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology. 2001; 25(5):757-65. DOI: 10.1016/S0893-133X(01)00273-1. View